Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity

US7745691B2 · kind B2 · utility

Assignees

• The Regents of the University of California · US
• DEPARTMENT OF VETERANS AFFAIRS · US
• THE J. DAVID GLADSTONE INSTITUTES · US

Inventors

• Robert Farese · San Francisco, US
• Hubert Chen · Taichung, TW
• Steven Smith · The Bronx, US
• Sylvaine Cases · Belmont, US
• Sandra K. Erickson · San Francisco, US

Key dates

• Filing date: Dec 12, 2006
• Grant date: Jun 29, 2010
• Expiry date: Jun 14, 2027

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/042
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake into cells and assimilation into glycogen. Also provided are pharmaceutical compositions for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering conditions associated with abnormal carbohydrate metabolism, such as obesity or diabetes.